keyword
MENU ▼
Read by QxMD icon Read
search

poor ovarian response

keyword
https://www.readbyqxmd.com/read/29336996/follicular-flushing-in-patients-with-poor-ovarian-response-a-systematic-review-and-meta-analysis
#1
REVIEW
Kay Neumann, Georg Griesinger
To evaluate the effect of follicular flushing on clinical outcomes (primary outcome: mean number of COCs) in poor response IVF patients a systematic literature review and meta-analysis was performed. The bibliographic databases OvidMedline (includes Pubmed), Cochrane Library and Web of Science were searched electronically for randomized controlled trials (RCTs) comparing follicular flushing with no flushing. Three RCTs with a total of 210 patients could be included. The mean number of COC did not increase with flushing (weighted mean difference: -0...
December 29, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/29334771/development-of-anti-human-mesothelin-targeted-chimeric-antigen-receptor-car-messenger-rna-mrna-transfected-peripheral-blood-lymphocytes-carma-hmeso-for-ovarian-cancer-therapy
#2
Chien-Fu Hung, Xuequn Xu, Linhong Li, Ying Ma, Qiu Jin, Angelia Viley, Cornell Allen, Pachai Natarajan, Rama Shivakumar, Madhusudan V Peshwa, Leisha A Emens
CD19-targeted chimeric antigen receptor (CAR) engineered T/natural kill (NK)-cell therapies can result in durable clinical responses in B-cell malignancies. However, CAR-based immunotherapies have been much less successful in solid cancers, in part due to 'on-target off-tumor' toxicity related to expression of target tumor antigens on normal tissue. Based on preliminary observations of safety and clinical activity in proof-of-concept clinical trials, tumor antigen-specific messenger RNA (mRNA) CAR transfection into selected, activated, and expanded T/NK-cells may permit prospective control of 'on-target off-tumor toxicity'...
January 15, 2018: Human Gene Therapy
https://www.readbyqxmd.com/read/29327913/proteomic-analysis-of-the-downstream-signaling-network-of-parp1
#3
Yuanli Zhen, Yonghao Yu
Poly-ADP-ribosylation (PARylation) is a protein posttranslational modification (PTM) that is critically involved in many biological processes that are linked to cell stress responses. It is catalyzed by a class of enzymes known as poly-ADP-ribose polymerases (PARPs). In particular, PARP1 is a nuclear protein that is activated upon sensing nicked DNA. Once activated, PARP1 is responsible for the synthesis of a large number of PARylated proteins and initiation of the DNA damage response (DDR) mechanisms. This observation provided the rationale for developing PARP1 inhibitors for the treatment of human malignancies...
January 12, 2018: Biochemistry
https://www.readbyqxmd.com/read/29324533/multicenter-clinicopathological-study-of-high-grade-serous-carcinoma-presenting-as-primary-peritoneal-carcinoma
#4
Shinichi Komiyama, Yoshihiro Nishijima, Haruhiro Kondo, Hiroyuki Nomura, Satoshi Yamaguchi, Masayuki Futagami, Hiroharu Arai, Yoshihito Yokoyama, Nao Suzuki, Mikio Mikami, Kaneyuki Kubushiro, Daisuke Aoki, Yasuhiro Udagawa, Ryuichiro Nishimura
OBJECTIVE: We conducted a multicenter clinicopathological study to characterize patients with high-grade serous carcinoma presenting as primary peritoneal carcinoma (clinical PPC). METHODS: At 9 sites in Japan, patients with clinical PPC diagnosed according to Gynecologic Oncology Group criteria were enrolled retrospectively. The Gynecologic Oncology Group criteria allow for minor ovarian involvement by high-grade serous carcinoma. There was no systematic detailed histopathological review of the fallopian tubes to determine whether they were involved by serous carcinoma...
January 10, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29303236/andro-ivf-a-novel-protocol-for-poor-responders-to-ivf-controlled-ovarian-stimulation
#5
Ludmila Bercaire, Sara Mb Nogueira, Priscila Cm Lima, Vanessa R Alves, Nilka Donadio, Artur Dzik, Mario Cavagna, Renato Fanchin
OBJECTIVE: This study aimed to assess a novel protocol designed to improve poor ovarian response through intra-ovarian androgenization. The endpoints were: number of oocytes and mature oocytes retrieved, fertilization, cancellation and pregnancy rates. METHODS: This prospective crossover study enrolled poor responders from previous ovarian stimulation cycles submitted to a novel protocol called ANDRO-IVF. The protocol included pretreatment with transdermal AndroGel(r) (Besins) 25 mg, oral letrozole 2...
January 5, 2018: JBRA Assisted Reproduction
https://www.readbyqxmd.com/read/29298656/pre-clinical-validation-of-mito-targeted-nano-engineered-flavonoids-isolated-from-selaginella-bryopteris-sanjeevani-as-a-novel-cancer-prevention-strategy
#6
Arpit Bhargava, Neelam Pathak, Sriram Seshadri, Neha Bunkar, Subodh Kumar Jain, Dinesh Mishra Kumar, Nirmal Kumar Lohiya, Pradyumna Kumar Mishra
BACKGROUND: Novel bioactive plant secondary metabolites, including flavonoids, offer a spectrum of chemo-protective responses against a range of human tumor models. However, the clinical translation of these promising anti-cancer agents has been hindered largely by their poor solubility, rapid metabolism, or a combination of both, ultimately resulting in poor bioavailability upon oral administration. OBJECTIVE: To circumvent the challenges associated with herbal drug development and for effective integration into clinical setting, nano-engineering is one of the emerging pragmatic strategy which has promise to deliver therapeutic concentrations of bio-actives upon oral administration...
December 29, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29258385/a-comparison-of-treatment-results-of-the-different-treatment-protocols-in-patients-with-poor-ovarian-response
#7
Ilhan Sanverdi, Huseyin Tayfun Kutlu, Bulent Emre Bilgic, Adnan Incebiyik
To compare the effect of the different protocols in patients receiving in vitro fertilization treatment due to poor ovarian response. Seventy-seven of the patients included in the study were treated with gonadotropin (450 IU) + GnRH antagonist (group 1), 84 of the patients were treated with gonadotropin (450 IU) + microdose GnRH analog (group 2), and 53 of the patients were treated with clomiphene citrate (100 mg/day) + gonadotropin (300 IU) + GnRH antagonist (Group 3). In assessing total gonadotropin dosage, patients in Group 3 detected significantly less gonadotropin as compared to the other two groups (p < ...
December 19, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29250192/creb5-promotes-tumor-cell-invasion-and-correlates-with-poor-prognosis-in-epithelial-ovarian-cancer
#8
Shanyang He, Yalan Deng, Yanbin Liao, Xiaojin Li, Jun Liu, Shuzhong Yao
CAMP responsive element binding protein 5 (CREB5) has crucial roles in regulating cell growth, proliferation, differentiation and cell cycle regulation. CREB5 has been identified to be overexpressed in several types of human cancer. However, the expression characteristics of CREB5 in epithelial ovarian cancer remains unknown, and its potential clinical prognostic significance has not yet been elucidated. In the present study, quantitative polymerase chain reaction (qPCR) and western blot analysis were performed to detect CREB5 mRNA and protein expression levels in 10 fresh tissue and cell lines epithelial ovarian cancer...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29246147/health-care-professionals-attitudes-towards-population-based-genetic-testing-and-risk-stratification-for-ovarian-cancer-a-cross-sectional-survey
#9
Katie E J Hann, Lindsay Fraser, Lucy Side, Sue Gessler, Jo Waller, Saskia C Sanderson, Madeleine Freeman, Ian Jacobs, Anne Lanceley
BACKGROUND: Ovarian cancer is usually diagnosed at a late stage when outcomes are poor. Personalised ovarian cancer risk prediction, based on genetic and epidemiological information and risk stratified management in adult women could improve outcomes. Examining health care professionals' (HCP) attitudes to ovarian cancer risk stratified management, willingness to support women, self-efficacy (belief in one's own ability to successfully complete a task), and knowledge about ovarian cancer will help identify training needs in anticipation of personalised ovarian cancer risk prediction being introduced...
December 16, 2017: BMC Women's Health
https://www.readbyqxmd.com/read/29245977/the-cancer-testis-antigen-sperm-protein-17-a-new-biomarker-and-immunological-target-in-head-and-neck-squamous-cell-carcinoma
#10
Christopher A Schutt, Leonardo Mirandola, Jose A Figueroa, Diane D Nguyen, Joehassin Cordero, Klauss Bumm, Benjamin L Judson, Maurizio Chiriva-Internati
Head and Neck Squamous Cell Carcinoma is a deadly and locally aggressive malignancy that frequently portends a poor prognosis. Since current treatment modalities including surgery, chemotherapy and radiation are heavily debilitating and often result in recurrence intense efforts have been put into the development of novel less toxic and more lasting treatment strategies. Recently, immunotherapy has been proposed as a promising alternative that could potentially meet these requirements. SP17 is a validated cancer-testis antigen in multiple myeloma, ovarian cancer and non-small cell lung cancer...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29245250/inositol-supplement-improves-clinical-pregnancy-rate-in-infertile-women-undergoing-ovulation-induction-for-icsi-or-ivf-et
#11
REVIEW
Xiangqin Zheng, Danmei Lin, Yulong Zhang, Yuan Lin, Jianrong Song, Suyu Li, Yan Sun
OBJECTIVE: Pretreatment of myoinositol is a very new method that was evaluated in multiple small studies to manage poor ovarian response in assisted reproduction. This study was to determine the efficacy of myoinositol supplement in infertile women undergoing ovulation induction for intracytoplasmic sperm injection (ICSI) or in vitro fertilization embryo transfer (IVF-ET). METHODS: A meta-analysis and systematic review of published articles evaluating the efficacy of myo-inositol in patients undergoing ovulation induction for ICSI or IVF-ET was performed...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29243796/can-high-levels-of-d-chiro-inositol-in-follicular-fluid-exert-detrimental-effects-on-blastocyst-quality
#12
K Ravanos, G Monastra, T Pavlidou, M Goudakou, N Prapas
OBJECTIVE: It was previously shown that higher concentrations of myo-inositol in human follicular fluid improve oocyte and embryo quality, whereas D-chiro-inositol seems to worsen oocyte quality and ovarian response in polycystic ovary syndrome patients. Our study was the first one aiming to test whether different myo-inositol and D-chiro-inositol concentration in follicular fluids correlate with blastocyst quality in healthy young women. PATIENTS AND METHODS: Eight egg donors and eleven couples undergoing in vitro fertilization, were involved in a prospective observational study...
December 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29233887/st6gal-i-sialyltransferase-promotes-tumor-necrosis-factor-tnf-mediated-cancer-cell-survival-via-sialylation-of-the-tnf-receptor-1-tnfr1-death-receptor
#13
Andrew T Holdbrooks, Colleen M Britain, Susan L Bellis
Activation of the TNFR1 death receptor by TNF induces either cell survival or cell death. However, the mechanisms mediating these distinct outcomes remain poorly understood. In the present study, we report that the ST6Gal-I sialyltransferase, an enzyme upregulated in numerous cancers, sialylates TNFR1, and thereby protects tumor cells from TNF-induced apoptosis. Using pancreatic and ovarian cancer cells with ST6Gal-I knockdown or overexpression, we determined that α2-6 sialylation of TNFR1 had no effect on early TNF-induced signaling events including the rapid activation of NFκB, JNK, ERK, and Akt (occurring within 15m)...
December 12, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29232470/how-can-molecular-abnormalities-influence-our-clinical-approach
#14
W Wei, F Giulia, S Luffer, R Kumar, B Wu, M Tavallai, R T Bekele, M J Birrer
Background: Despite improvements in diagnostics and treatment, the clinical outcome of epithelial ovarian cancer remains poor over the last three decades. Recent high-throughput genomic studies have demonstrated ovarian cancer as a highly heterogeneous entity with distinctive molecular signatures among different or even within the same histotype. In this article, we review the molecular genetics of epithelial ovarian cancer and how they have been translated into modern clinical trials, as well as their implications in patient stratification for more targeted and personalized approaches...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29223475/insights-from-clinical-experience-in-treating-ivf-poor-responders
#15
REVIEW
Kelly J Gonda, Alice D Domar, Norbert Gleicher, Richard P Marrs
'Poor responders' is a term used to describe a subpopulation of IVF patients who do not respond well to ovarian stimulation with gonadotrophins. While there is no standard definition of a poor responder, these patients tend to be of advanced maternal age (≥40 years), have a history of poor ovarian response with conventional stimulation protocols, and/or have low ovarian reserve. Despite the heterogeneity of this patient group, there are characteristics and needs common to many poor responders that can be addressed through a holistic approach...
October 24, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/29212257/lentiviral-crispr-cas9-nickase-vector-mediated-birc5-editing-inhibits-epithelial-to-mesenchymal-transition-in-ovarian-cancer-cells
#16
Guannan Zhao, Qinghui Wang, Qingqing Gu, Wenan Qiang, Jian-Jun Wei, Peixin Dong, Hidemichi Watari, Wei Li, Junming Yue
BIRC5 encodes the protein survivin, a member of the inhibitor of apoptosis family. Survivin is highly expressed in a variety of cancers but has very low expression in the corresponding normal tissues, and its expression is often associated with tumor metastasis and chemoresistance. We report that survivin was highly expressed in ovarian cancer and strongly correlated with patient overall poor survival. For the first time, we provide experimental evidence that survivin is involved in epithelial to mesenchymal transition (EMT) in ovarian cancer cells...
November 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/29208204/durable-renal-response-after-combination-of-bortezomib-corticosteroids-rituximab-and-plasmapheresis-for-late-antibody-mediated-renal-transplant-rejection%C3%A2
#17
Yanli Ding, Jean Francis, Amitabh Gautam, Linda Pelletier, Vaishali Sanchorawala, Karen Quillen
Late occurrence of antibody-mediated rejection (AMR), defined as occurring 6 months after transplantation, is associated with poor renal allograft survival, compared to early acute AMR and acute cellular rejection. The proteasome inhibitor bortezomib has multiple immunomodulatory effects on plasma cells, the source of donor-specific HLA antibodies which mediate AMR. MATERIALS AND METHODS: Consecutive patients who presented with biopsy-proven AMR and donor-specific anti-HLA antibodies (DSA) at a single institution between July 2011 and February 2015 were included...
December 6, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/29203984/ovarian-metastases-of-colorectal-origin-treatment-patterns-and-factors-affecting-outcomes
#18
Praveen S Kammar, Reena Engineer, Prachi S Patil, Vikas Ostwal, T S Shylasree, Avanish P Saklani
The purpose of this study is to evaluate the patterns of treatment and factors affecting outcomes in ovarian metastases of colorectal origins treated at our institution and to assess the response of ovarian metastases to chemotherapy. Survival in R0 and R+ resections and patients receiving only chemotherapy is also analyzed. This is a retrospective study of 25 patients registered between January 2012 and December 2015. Patient's age, disease status, mode of presentation, disease spread, mode of treatment, response to chemotherapy, completeness of resection, histology, and outcomes were considered as variables for analysis...
December 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29201666/occult-form-of-premature-ovarian-insufficiency-in-women-with-infertility-and-oligomenorrhea-as-assessed-by-poor-ovarian-response-criteria
#19
Rubina Izhar, Samia Husain, Suhaima Tahir, Sonia Husain
Background: The purpose of this study was to evaluate the ability of poor ovarian response criteria to classify women presenting with infertility and oligomenorrhea as having "occult" premature ovarian insufficiency. Methods: This was a cross sectional study conducted at Aziz Medical Center, Karachi, Pakistan from 1st August 2015 to 31st July 2016. Women with infertility and oligomenorrhea were included. All eligible women underwent day 2 FSH level and an early follicular phase transvaginal ultrasound to assess the antral follicular count (AFC)...
October 2017: Journal of Reproduction & Infertility
https://www.readbyqxmd.com/read/29195015/does-using-testicular-sperm-retrieval-rather-than-ejaculated-spermatozoa-improve-reproductive-outcomes-in-couples-with-previous-art-failure-and-poor-ovarian-response-a-case-controlled-study
#20
A R Gilman, G Younes, S Tannus, W Y Son, P Chan, W Buckett
The objective of this study was to assess whether testicular-retrieved spermatozoa improve reproductive outcomes compared to fresh ejaculate in women with poor ovarian response and a history of previous ART failure. The study was performed as a retrospective case-control study at a university-based reproductive center in Montreal, Quebec, Canada. Eighteen poor-responder patients were matched 3 : 1 with 54 controls. Poor responders were defined as those with ≤3 oocytes retrieved at oocyte pickup. Cases were identified as poor responders, and only those with previous IVF failure(s) as an indication for testicular-retrieved spermatozoa were included...
January 2018: Andrology
keyword
keyword
57151
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"